Mineralys Therapeutics Inc. reported its financial results for the first quarter ended March 31, 2025. The company recorded a net loss of $42.2 million, up from $31.5 million for the same period in 2024. This increase in net loss was mainly due to higher general and administrative expenses, which rose to $6.6 million from $4.6 million, largely driven by greater compensation expenses and professional fees. Research and Development expenses also increased to $37.9 million from $30.8 million, attributed to higher preclinical and clinical costs and compensation expenses. Total other income decreased to $2.2 million from $3.9 million, primarily due to lower interest earned on investments. Mineralys reported cash, cash equivalents, and investments of $343.0 million as of March 31, 2025, up significantly from $198.2 million as of December 31, 2024. The company anticipates that these funds will support its planned clinical trials and regulatory activities into 2027. Notably, Mineralys achieved statistical significance in its pivotal Advance-HTN and Launch-HTN trials, demonstrating favorable safety and tolerability. The company also initiated the Explore-OSA Phase 2 trial in the first quarter of 2025 and expects to deliver topline data from the Explore-CKD Phase 2 trial in the second quarter of 2025.